20/20 Biolabs (AIDX) Fundamental Analysis: Revenue, Earnings & Valuation

5.47 / 10

Netural

Corporate fundamentals rate average at 5.5/10. Beneficial factors: Profit-MV and Inventory turnover days, balanced by issues in Total profit (YoY growth rate %) and Cash-MV. Resultant assessment: moderate.

Analysis Checks(6/9)

Revenue-MV

Value-0.18

Score0/3

Weight-8.13%

1M Return-2.47%

Net cash flow from operating activities per share (YoY growth rate %)

Value54251.67

Score3/3

Weight27.06%

1M Return5.69%

Profit-MV

Value0.62

Score2/3

Weight14.92%

1M Return3.69%

Basic earnings per share (YoY growth rate %)

Value34.48

Score2/3

Weight10.70%

1M Return2.57%

Total profit (YoY growth rate %)

Value32.65

Score1/3

Weight8.48%

1M Return1.95%

Net cash flow from operating activities (YoY growth rate %)

Value26.13

Score2/3

Weight16.61%

1M Return3.64%

Diluted earnings per share (YoY growth rate %)

Value34.48

Score2/3

Weight8.63%

1M Return2.10%

Inventory turnover days

Value20.41

Score3/3

Weight20.15%

1M Return4.33%

Cash-MV

Value0.01

Score0/3

Weight1.57%

1M Return0.49%

Is AIDX fundamentally strong?

AIDX scores 5.47/10 on fundamentals and holds a Fair valuation at present. Backed by its -503.12% ROE, -182.82% net margin, -5.25 P/E ratio, -1021.21 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.